Dipyridamole potentiates the growth-inhibitory action of methotrexate and 5-fluorouracil in human keratinocytes in vitro.
Human keratinocytes transport extracellular thymidine across the plasma membrane and incorporate it into DNA. Data presented here show that dipyridamole, a well-known inhibitor of facilitated diffusion of nucleosides, blocks the transport of thymidine into human keratinocytes in vitro. Dipyridamole (1.0 microM) inhibited the transport of 3H-thymidine (0.2 microM) into intracellular material by 75% and its subsequent salvage and incorporation into DNA by 48%. Dipyridamole (1 microM) did not affect the growth of keratinocytes in vitro but did potentiate the growth inhibition caused by methotrexate (MTX) or 5-fluorouracil (5-FU). The growth of keratinocytes exposed to 0.1 microM MTX for 8 d was inhibited by 32%. However, in combination with a noninhibitory concentration of dipyridamole (1 microM), this concentration of MTX (0.01 microM) inhibited the growth of keratinocytes by 93%. Thymidine in culture medium reversed the cytotoxicity of MTX. However, in the presence of dipyridamole, thymidine in the culture medium did not reverse the action of MTX. The synergistic interaction between MTX and dipyridamole was also observed with 5-FU and dipyridamole. 5-FU (0.5 microM) inhibited cell growth by 30% but in combination with dipyridamole (1 microM), inhibited cell growth by 86%. These data are consistent with the theory that inhibiting thymidine salvage by blocking transport of extracellular thymidine potentiates the growth inhibitory action of inhibitors of de novo pyrimidine biosynthesis in human keratinocytes. Combination chemotherapy, such as methotrexate plus dipyridamole, might be efficacious in the treatment of hyperproliferative diseases of the epidermis.
Schwartz
P M
PM
Dermatology Service, VA Medical Center, West Haven, CT 06516.
Milstone
L M
LM
D002455:Cell Division / Q000187:drug effects; D004247:DNA / Q000378:metabolism; D004176:Dipyridamole / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004357:Drug Synergism / Q000187:drug effects; D000078404:Epidermal Cells; D005472:Fluorouracil / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D007231:Infant, Newborn; D007633:Keratins / Q000378:metabolism*; D008297:Male; D008727:Methotrexate / Q000378:metabolism* / Q000494:pharmacology; D013936:Thymidine / Q000378:metabolism
D004176:Dipyridamole; D007633:Keratins; D004247:DNA; D005472:Fluorouracil; D013936:Thymidine; D008727:Methotrexate